In the fourth blog in our series looking at the story behind the EFPIA Manifesto, Sini Eskola, Director of Regulatory, Drug Development and Manufacturing at EFPIA looks at the case for fast-tracking advanced therapies for patients across Europe.
Our vision is to improve Europe’s capability to fast-track breakthrough therapies which meet the unmet medical needs of patients. Key to realising that ambition is ensuring that the European Medicines Agency (EMA) has the resources and flexibility to be at the forefront of regulatory excellence globally. This is even more critical in the context of the challenges presented by the Agency’s relocation as a result of Brexit.
Demystifying Clinical Data Transparency: Lessons learnt so far
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.